NATCO Pharma Limited has announced the successful completion of United States Food and Drug Administration's (USFDA) inspection of the firm's compliance to Pharmacovigilance requirements with zero observations.

NATCO's Pharmacovigilance Department, at its Corporate Office in Hyderabad, was inspected from October 30, 2023 to November 1, 2023. The Pharmacovigilance procedures of NATCO for its products marketed globally and particularly, in USA, were inspected and found to comply with USFDA's requirements.